MarketPulse
B

$BMEA

3 articles found
3 positive
0 negative
0 neutral
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Biomea Fusion to Present Icovamenib Diabetes Data at ADA Conference

Biomea Fusion selected for three late-breaking poster presentations on icovamenib at ADA 86th Scientific Sessions in June 2026, showcasing Phase 2 trial results.
BMEAPhase 2 clinical trialType 1 diabetes
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Biomea Fusion Advances Diabetes Drug With Two Phase II Studies as Treatment Gap Widens

Biomea Fusion initiates two Phase II trials of icovamenib for type 2 diabetes patients failing standard therapies, building on earlier positive data showing durable HbA1c reductions.
BMEAType 2 diabetesicovamenib
GlobeNewswire Inc.GlobeNewswire Inc.··Biomea Fusion, Inc.

Biomea Fusion's Diabetes Drug Shows Durable Benefits Nine Months Post-Dose

Biomea Fusion presents positive Phase II data for icovamenib in type 2 diabetes, showing durable 1.2% HbA1c reduction nine months after dosing with favorable safety profile.
BMEAobesityType 2 diabetes